Understanding heart damage from severe pneumonia
Cardiac microlesion formation during invasive pneumococcal disease
This work aims to understand why a specific type of pneumonia bacteria causes serious heart problems in adults, hoping to find new ways to protect patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10878075 on NIH RePORTER |
What this research studies
Many adults hospitalized with pneumonia caused by Streptococcus pneumoniae bacteria can experience severe heart complications, which makes their illness much more dangerous. This particular project focuses on a highly aggressive and drug-resistant strain of this bacteria, called GPSC10, which is especially prone to causing heart damage. Our goal is to pinpoint the specific genetic factors that make GPSC10 so harmful to the heart. By identifying these factors, we hope to discover new targets for treatments or vaccines that could prevent these life-threatening heart issues.
Who could benefit from this research
Good fit: Ideal candidates for future related studies might include adults aged 21 and older who are at risk for or have experienced severe pneumonia with associated cardiac complications.
Not a fit: Patients without severe pneumococcal pneumonia or those not experiencing associated cardiac events may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new treatments or preventive strategies to protect patients from severe heart damage caused by pneumonia.
How similar studies have performed: Pilot studies have already shown promising initial findings, suggesting that this approach of identifying specific bacterial factors is a viable path forward.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Orihuela, Carlos J — University of Alabama at Birmingham
- Study coordinator: Orihuela, Carlos J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.